



STATE MEDICAID P&T COMMITTEE MEETING  
 THURSDAY, September 15, 2011  
 7:00 a.m. to 8:30 a.m.  
 Cannon Health Building  
 Room 114



# MINUTES

**Committee Members Present:**

**Kort DeLost, R.Ph.**

**Karen Gunning, Pharm.D.**

**Lisa Hunt, R.Ph.**

**Brandon Jennings, Pharm.D.**

**Bernadette Kiraly, M.D.**

**Roger Martenau, M.D.**

**Julia Ozbolt, M.D.**

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Tim Morley, R.Ph.

Joe Cramer, Medicaid Medical Director

Robyn Seely, Pharm.D.

**University of Utah Drug Information Center Staff Present:**

Gary Oderda, Pharm.D.

Melissa Archer, Pharm.D.

**Other Individuals Present:**

Rachel Bevis, AstraZeneca

Mandy Hosford, AstraZeneca

John Brokars, Eil Lilly

Trish McDaid-O'Neill, AstraZeneca

Scott Clegg, Eli Lilly

Laura Zagnoni, Bristol-Myers Squibb

Meeting conducted by: Karen Gunning Pharm.D., Co-Chairperson.

---

**NOTE: Audio recording for this meeting malfunctioned; these minutes are comprised of notes various attendees wrote.**

- 1 Review and Approval of Minutes: Brandon Jennings moved to approve the minutes. Kort DeLost seconded the motion. The motion was approved unanimously by Karen Gunning, Lisa Hunt, Bernadetta Kiraly, and Roger Martenau.
- 2 Housekeeping: None
- 3 DUR Board Update: Robyn Seely addressed the Committee. In September, the DUR Board discussed new treatments for Hepatitis C. Victrelis and Incevek remain available without PA. High-dose simvastatin was discussed. A PA will be required for all patients seeking the 80mg dose. Those currently taking 80mg will be grandfathered and allowed to continue. Next month the DUR Board will be discussing Brillinta and Xarelto.
- 4 Melissa Archer from the University of Utah presented research on platelet aggregation inhibitors (including aspirin, aspirin/dipyridamole, clopidogrel,

cilostazol, dipyridamole, prasugrel, ticlopidine, and ticagrelor).

Lisa Hunt provided the Oregon Health and Science University's Drug Class Review on Newer Antiplatelet Agents for reference. Also provided were example PDLs from Iowa, Maine, Vermont, and West Virginia to illustrate other states' coverage.

a. Public Comment

- i. Mandy Hosford, AstraZeneca, addressed the Committee regarding ticagrelor (Brillinta®).
- ii. Laura Zagnoni, Bristol-Myers Squibb, addressed the Committee regarding clopidogrel (Plavix®). She noted that the patent expires in May 2012, at which time several very inexpensive generic products will become available.
- iii. John Brokars, Eli Lilly, addressed the Committee regarding prasugrel (Effient®).

b. Committee Action

- i. Kori DeLost moved that the formulary include aspirin and clopidogrel. Burnadette Kiraly seconded the motion.
- ii. Kori DeLost moved that the formulary not include ticlopidine. Julia Ozbolt seconded the motion.
- iii. Lisa Hunt moved that, while each has unique indications, the remaining drugs are each safe and efficacious for their target populations. Julia Ozbolt seconded the motion.
- iv. Burnadette Kiraly suggested that the online PDL table be very clear about each drug's indications and contraindications. She felt this would guide prescribers to choosing the preferred product most appropriate for their patient's diagnosis and treatment goals. Brandon Jennings supported this idea.

Next Meeting Set for Thursday, October 20, 2011

Meeting Adjourned.

Minutes prepared by Robyn Seely from notes taken at the meeting. No audio recording available.